CTI BioPharma Corp

Most Recent

  • uploads///hand _
    Company & Industry Overviews

    CTI BioPharma Has Fallen Almost 39% Today

    On July 18, CTI BioPharma announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib.

    By Margaret Patrick
  • uploads///Kymriah
    Company & Industry Overviews

    How Is Novartis’s Kymriah Positioned for 2018?

    FDA and EC approvals for label expansion are expected to further boost Kymriah’s sales growth.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.